Complete Profile

Wex Pharmaceuticals Inc.

Last Updated: 2009-03-12
	Legal Name:   Wex Pharmaceuticals Inc.
	Operating Name:   Wex Pharmaceuticals Inc.
	Mailing Address 1601-700 Pender St W VANCOUVER, British Columbia V6C 1G8	Location Address 1601-700 Pender St W VANCOUVER, British Columbia V6C 1G8
	Telephone: (604) 683-8880
	Toll Free Phone: 1(800) 722-7549
	Fax: (604) 683-8868
	Email: wex@wexpharma.com
	Website URL: http://www.wexpharma.com

Contact Information

Dan Carey
	Title:   Director, Business Development
	Telephone:   (604) 676-7894
	Fax:   (604) 683-8868
	Email:   danc@wexpharma.com
Bin Huang
	Title:   Chief Executive Officer
	Telephone:   (604) 683-8880
	Fax:   (604) 683-8868
Mike Lam
	Title:   Chief Financial Officer
	Telephone:   (604) 683-8880
	Fax:   (604) 683-8868
Peter Stafford
	Title:   Corporate Secretary
	Telephone:   (604) 683-8880
	Fax:   (604) 683-8868
Anh Ho Ngoc
	Title:   V.P. Scientific & Regulatory Affairs
	Area of Responsibility:   Research/Development/Engineering
	Telephone:   (604) 683-8880
	Fax:   (604) 683-8868

Company Description

Wex Pharmaceuticals Inc. (the "Company") is a neuro- bioscience company, federally incorporated in Canada in 1992, dedicated to the discovery of medicine for the management of pain in order to minimize human suffering. The Company is a leader in the extraction, refinement and manufacture of Tetrodotoxin (TTX), a purified complex, non-protein toxin extracted from the puffer fish. The Company initially identified TTX for use in the management of pain and other symptoms associated with withdrawal from prescription and non- prescription opiates, and used the trade name Tetrodin™ for this indication. The Company also conducted research on the analgesic effects of TTX in order to determine the potential for the market for the management of chronic and acute pain. The trade name Tectin™ is used for these potential analgesic indications. In animal studies involving TTX, the potential of the drug substance for use as a local or regional anesthetic was also identified. The Company uses the trade name Tocudin™ for these anesthetic indications. Since the company's public listing on the Canadian Ventures Exchange in 1992 to the present, substantial capital has been directed to the research and development of various drugs, and subsequently, the protection of our intellectual knowledge by filing multiple patents. The lead products, Tetrodin™ and Tectin™ are being processed through the regulatory channels for approvals in Canada, United States and Europe, and ultimately pharmaceutical sales.
Country of Ownership:	Canada
Year Established:	1992
Exporting:	Yes
Primary Industry (NAICS):	325410 - Pharmaceutical and Medicine Manufacturing
Primary Business Activity:	Manufacturer / Processor / Producer
Number of Employees:	12

Product / Service / Licensing

Product Name:	Tectin™ (Exporting)
Initial research by the Company into tetrodotoxin (TTX) focused on the indications of opiate addiction withdrawal, but, in the early phase of pharmacological studies of TTX, it became apparent that the prime factor in its ability to reduce or eliminate the severe symptoms of withdrawal was its ability to reduce pain. The Company therefore pursued further research on the ability of TTX to alleviate pain and obtained positive results developing a revolutionary non-narcotic pharmaceutical with potent properties called Tectin™. Tectin™ is ideal for management of severe pain, including palliative cancer pain.
Product Name:	Tetrodin™ (Exporting)
A revolutionary non-narcotic pharmaceutical, with potent analgesic properties, developed from the naturally organic substance tetrodotoxin (TTX). Tetrodin™, with experiments to date, has shown to provide a safe, cost effective primary withdrawal treatment solution for heroin and other opiate addiction to substances such as morphine, opium and methadone.
Product Name:	Tocudin™ (Exporting)
Targeted at the local and topical anesthetic market, for patients undergoing surgery or procedures for which general anesthesia (loss of consciousness) may be impractical or unnecessary, Tocudin™ is undergoing intensive preclinical testing at the world-renowned Beijing Medical University in China, where the Company's research & development and manufacturing operations are currently located, resulting to date in positive and very promising results.

Market Profile

Industry Sector Market Interests: Medical/Biotechnology/Chemical